Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
306. |
ECCT/18/07/06 | Hestia 3 A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Prof Jessie Nyokabi Githanga 2. Videlis Nduba 3. Janet N Oyieko 4. Bernards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Chandaria Health Center Clinical Research Clinic (Nairobi City county) 3. Kenya Medical Research Institute (KEMRI) Kisumu (Kisumu county) 4. KEMRI Kombewa Clinical Research Centre (Nairobi City county) 5. Kondele Children\'s Hospital (Kisumu county) 6. Strathmore University Medical Centre (Nairobi City county) |
View |
307. |
ECCT/18/07/02 | CONRAD RING Phase IIa, 90-Day Safety, Adherence, and Acceptability Study of Intravaginal Rings Releasing Tenofovir with and without Levonorgestrel among Women in Western Kenya |
Principal Investigator(s) 1. DR. NELLY RWAMBA MUGO Site(s) in Kenya KEMRI CRC |
View |
308. |
ECCT/18/06/04 | RANDOMIZED CONTROLLED TRIAL OF STEPPED UP VITAMIN A SUPPLEMENTATION DOSE ON IMMUNE RESPONSES AMONG INFANTS 6-12 MONTHS AT BUSIA LEVEL 4 HOSPITAL IN BUSIA COUNTY, KENYA BUSIA LEVEL IV HOSPITAL |
Principal Investigator(s) 1. BENARD OCHIENG WESONGA Site(s) in Kenya Busia Level IV Hospital |
View |
309. |
ECCT/18/07/03 | Development of innovative integrated system to reduce malaria transmission towards elimination in the Lake Victoria basin, Kenya Development of innovative integrated system to reduce malaria transmission towards elimination in the Lake Victoria basin, Kenya |
Principal Investigator(s) 1. WATARU KAGAYA 2. KINYA UCHIHASHI Site(s) in Kenya HOMA BAY DISTRICT HOSPITAL |
View |
310. |
ECCT/18/07/07 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. GRACE KIRINGA KAGUTHI Site(s) in Kenya 1. Center for Respiratory Diseases Research (Siaya county) 2. KEMRI (Kisumu county) |
View |